117 related articles for article (PubMed ID: 38676689)
1. [Associations of serum neuromarkers with clinical features of Parkinson's disease].
Nikitina MA; Koroleva ES; Brazovskaya NG; Boyko AS; Levchuk LA; Ivanova SA; Alifirova VM
Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(4):145-152. PubMed ID: 38676689
[TBL] [Abstract][Full Text] [Related]
2. Identification of BAG2 and Cathepsin D as Plasma Biomarkers for Parkinson's Disease.
Kang J; Kim JW; Heo H; Lee J; Park KY; Yoon JH; Chang J
Clin Transl Sci; 2021 Mar; 14(2):606-616. PubMed ID: 33202088
[TBL] [Abstract][Full Text] [Related]
3. Do peripheral immune and neurotrophic markers correlate with motor severity of Parkinson's disease?
Roy A; Mondal B; Banerjee R; Choudhury S; Chatterjee K; Dey S; Kumar H
J Neuroimmunol; 2021 May; 354():577545. PubMed ID: 33756415
[TBL] [Abstract][Full Text] [Related]
4. Serum concentration and clinical significance of brain-derived neurotrophic factor in patients with Parkinson's disease or essential tremor.
Huang Y; Yun W; Zhang M; Luo W; Zhou X
J Int Med Res; 2018 Apr; 46(4):1477-1485. PubMed ID: 29350074
[TBL] [Abstract][Full Text] [Related]
5. Inflammatory markers and BDNF in obstructive sleep apnea (OSA) in Parkinson's disease (PD).
Kaminska M; O'Sullivan M; Mery VP; Lafontaine AL; Robinson A; Gros P; Martin JG; Benedetti A; Kimoff RJ
Sleep Med; 2022 Feb; 90():258-261. PubMed ID: 35228136
[TBL] [Abstract][Full Text] [Related]
6. Elevated levels of BDNF and cathepsin-d as possible peripheral markers of neurodegeneration in plasma of patients with glutaric acidemia type I.
Guerreiro G; Diaz Jaques CE; Wajner M; Vargas CR
Int J Dev Neurosci; 2020 Feb; 80(1):42-49. PubMed ID: 31910296
[TBL] [Abstract][Full Text] [Related]
7. Serum BDNF discriminates Parkinson's disease patients with depression from without depression and reflect motor severity and gender differences.
Huang Y; Huang C; Zhang Q; Wu W; Sun J
J Neurol; 2021 Apr; 268(4):1411-1418. PubMed ID: 33179143
[TBL] [Abstract][Full Text] [Related]
8. Association of low serum BDNF with depression in patients with Parkinson's disease.
Wang Y; Liu H; Du XD; Zhang Y; Yin G; Zhang BS; Soares JC; Zhang XY
Parkinsonism Relat Disord; 2017 Aug; 41():73-78. PubMed ID: 28576603
[TBL] [Abstract][Full Text] [Related]
9. Role of Apolipoprotein E, Cathepsin D, and Brain-Derived Neurotrophic Factor in Parkinson's Disease: A Study from Eastern India.
Pal P; Sadhukhan T; Chakraborty S; Sadhukhan S; Biswas A; Das SK; Ray K; Ray J
Neuromolecular Med; 2019 Sep; 21(3):287-294. PubMed ID: 31134487
[TBL] [Abstract][Full Text] [Related]
10. Serum levels of brain-derived neurotrophic factor correlate with motor impairment in Parkinson's disease.
Scalzo P; Kümmer A; Bretas TL; Cardoso F; Teixeira AL
J Neurol; 2010 Apr; 257(4):540-5. PubMed ID: 19847468
[TBL] [Abstract][Full Text] [Related]
11. New Clinical Subtypes of Parkinson Disease and Their Longitudinal Progression: A Prospective Cohort Comparison With Other Phenotypes.
Fereshtehnejad SM; Romenets SR; Anang JB; Latreille V; Gagnon JF; Postuma RB
JAMA Neurol; 2015 Aug; 72(8):863-73. PubMed ID: 26076039
[TBL] [Abstract][Full Text] [Related]
12. Serum level of brain-derived neurotrophic factor in Parkinson's disease: a meta-analysis.
Jiang L; Zhang H; Wang C; Ming F; Shi X; Yang M
Prog Neuropsychopharmacol Biol Psychiatry; 2019 Jan; 88():168-174. PubMed ID: 30017781
[TBL] [Abstract][Full Text] [Related]
13. Blood NfL: A biomarker for disease severity and progression in Parkinson disease.
Lin CH; Li CH; Yang KC; Lin FJ; Wu CC; Chieh JJ; Chiu MJ
Neurology; 2019 Sep; 93(11):e1104-e1111. PubMed ID: 31420461
[TBL] [Abstract][Full Text] [Related]
14. Systemic activation of NLRP3 inflammasome and plasma α-synuclein levels are correlated with motor severity and progression in Parkinson's disease.
Fan Z; Pan YT; Zhang ZY; Yang H; Yu SY; Zheng Y; Ma JH; Wang XM
J Neuroinflammation; 2020 Jan; 17(1):11. PubMed ID: 31915018
[TBL] [Abstract][Full Text] [Related]
15. Circulating levels of neurotrophic factors are unchanged in patients with Parkinson's disease.
Rocha NP; Ferreira JPS; Scalzo PL; Barbosa IG; Souza MS; Christo PP; Reis HJ; Teixeira AL
Arq Neuropsiquiatr; 2018 May; 76(5):310-315. PubMed ID: 29898077
[TBL] [Abstract][Full Text] [Related]
16. Gender differences in motor and non-motor symptoms among Sardinian patients with Parkinson's disease.
Solla P; Cannas A; Ibba FC; Loi F; Corona M; Orofino G; Marrosu MG; Marrosu F
J Neurol Sci; 2012 Dec; 323(1-2):33-9. PubMed ID: 22935408
[TBL] [Abstract][Full Text] [Related]
17. [Relationship between emotional apathy and motor symptoms, sleep and cognitive function in patients with early Parkinson's disease].
Chao JY; Xiong KP; Zhuang S; Zhang JR; Huang JY; Li J; Mao CJ; Wu HH; Wang JY; Liu CF
Zhonghua Yi Xue Za Zhi; 2021 Sep; 101(35):2792-2797. PubMed ID: 34551496
[No Abstract] [Full Text] [Related]
18. Constipation is not associated with dopamine transporter pathology in early drug-naïve patients with Parkinson's disease.
Pagano G; Yousaf T; Wilson H; Niccolini F; Polychronis S; Chaudhuri KR; Politis M
Eur J Neurol; 2018 Feb; 25(2):307-312. PubMed ID: 29078029
[TBL] [Abstract][Full Text] [Related]
19. Unveiling relevant non-motor Parkinson's disease severity symptoms using a machine learning approach.
Armañanzas R; Bielza C; Chaudhuri KR; Martinez-Martin P; Larrañaga P
Artif Intell Med; 2013 Jul; 58(3):195-202. PubMed ID: 23711400
[TBL] [Abstract][Full Text] [Related]
20. Prediction of depression and anxiety via patient-assessed tremor severity, not physician-reported motor symptom severity, in patients with Parkinson's disease or essential tremor who have undergone deep brain stimulation.
Achey RL; Yamamoto E; Sexton D; Hammer C; Lee BS; Butler RS; Thompson NR; Nagel SJ; Machado AG; Lobel DA
J Neurosurg; 2018 Dec; 129(6):1562-1571. PubMed ID: 29473781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
